Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G. Attia S, et al. Among authors: schelman wr. Cancer Chemother Pharmacol. 2009 Jun;64(1):45-51. doi: 10.1007/s00280-008-0844-1. Epub 2008 Oct 8. Cancer Chemother Pharmacol. 2009. PMID: 18841362 Free PMC article. Clinical Trial.
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
Tevaarwerk A, Wilding G, Eickhoff J, Chappell R, Sidor C, Arnott J, Bailey H, Schelman W, Liu G. Tevaarwerk A, et al. Invest New Drugs. 2012 Jun;30(3):1039-45. doi: 10.1007/s10637-010-9629-6. Epub 2011 Jan 12. Invest New Drugs. 2012. PMID: 21225315 Free PMC article. Clinical Trial.
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD. Choi BS, et al. Among authors: schelman wr. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80. doi: 10.1007/s00280-010-1250-z. Epub 2010 Feb 2. Cancer Chemother Pharmacol. 2010. PMID: 20127092 Free PMC article. Clinical Trial.
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
LoConte NK, Holen KD, Schelman WR, Mulkerin DL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, Robinson E, Lubner SJ. LoConte NK, et al. Among authors: schelman wr. Invest New Drugs. 2013 Aug;31(4):943-8. doi: 10.1007/s10637-012-9916-5. Epub 2012 Dec 21. Invest New Drugs. 2013. PMID: 23263993 Free PMC article. Clinical Trial.
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G. Schelman WR, et al. Invest New Drugs. 2014 Apr;32(2):295-302. doi: 10.1007/s10637-013-9999-7. Epub 2013 Jul 17. Invest New Drugs. 2014. PMID: 23860642 Free PMC article. Clinical Trial.
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Kolesar JM, et al. Among authors: schelman wr. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7. doi: 10.1007/s00280-013-2242-6. Epub 2013 Aug 1. Cancer Chemother Pharmacol. 2013. PMID: 23903894 Free PMC article. Clinical Trial.
41 results